Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint

Core Insights - The company has decided to discontinue the development of mRNA-1647, an investigational cytomegalovirus (CMV) vaccine [1] - The ongoing Phase 2 trial for mRNA-1647 in bone marrow transplant patients will continue [1] - The company does not expect any impact on its 2025 financial guidance or its goal of achieving breakeven by 2028 [1] Trial Results - The Phase 3 pivotal trial for mRNA-1647 did not meet its primary efficacy endpoint, which was to prevent CMV infection in seronegative female participants aged 16-40 [1]